Inflammatory bowel diseases: a new wave of therapy

Abstract

This review focuses on recent advances in the pathogenesis of inflammatory bowel diseases (IBDs) and current developments in claimed patents for the management of these diseases. These are developed in the hope of replacing conventional corticosteroids, 5-aminosalicylic acids (5-ASA) and immunosuppressants which have been the mainstay of therapy for decades. These patents represent a change in direction to more specific therapies to block a host of inflammatory mediators, either at their synthesis level or blocking binding to their designated receptors. The changes also represent a shift from synthetic inhibitors to biologicals for which the in vivo efficacy and side-effects need to be evaluated. These advancements represent a new wave of therapy to treat these debilitating diseases.

• adhesion molecule inhibition
• arachidonic acid inhibitors
• chemokine inhibitors
• Crohn’s disease
• cytokine inhibitors
• elastase inhibitors
• growth factors
• immunosuppressives
• inflammatory bowel disease
• nitric oxide inhibitors
• nuclear factor κB inhibitors
• superoxide dismutase mimics
• tachykinin antagonists
• tobacco products
• ulcerative colitis